Immunomodulation with low dose levamisole in patients with colonic polyps

Cancer Detection and Prevention

Volumn 30, Issue 1, 2006, Pages 94-98

  Holcombe, Randall F ^a   McLaren, Christine E ^a   Milovanovic, Tatjana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer prevention; Clinical design; Colonic polyps; Flow cytometry; Immunologic endpoints; Immunostimulatory activity; Interferon ; Levamisole; Peripheral blood mononuclear cells; Sample acquisition

Indexed keywords

ANTIGEN; CD16 ANTIGEN; CD56 ANTIGEN; CELL MARKER; GAMMA INTERFERON; LEVAMISOLE; PLACEBO;

ARTICLE; BASAL CELL; CANCER RISK; CD25+ T LYMPHOCYTE; CLINICAL TRIAL; COLON CANCER; COLON POLYP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL PROCEDURES; IMMUNOMODULATION; IMMUNOSTIMULATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; COLONIC NEOPLASMS; COLONIC POLYPS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LEVAMISOLE; PLACEBOS;

EID: 33644872551     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2005.08.002     Document Type: Article

References (22)

1. C.G. Moertel, T.R. Fleming, J.S. McDonald, D.G. Haller, J.A. Laurie, and P.J. Goodman Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma New Engl J Med 322 1990 352 358
2. J.A. Laurie, C.G. Moertel, T.R. Fleming, H.S. Wieand, J.E. Leigh, and J. Rubin Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil J Clin Oncol 7 1989 1447 1456
3. R.F. Holcombe, R.M. Stewart, K.W. Betzing, and K. Kannan Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil Cancer Immunol Immunother 34 1994 394 398
4. M. DeBrander, J. Vandebroek, H. Wassenaar, J. De Cree, A. Braisier, and B. Demoen Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU Anticancer Res 15 1995 2271 2277
5. J. Janik, W.C. Kopp, J.W. Smith, D.L. Longo, G. Alvord, and W.H. Sharfman Dose-related immunologic effects of levamisole in patients with cancer J Clin Oncol 11 1993 125 135
6. G.R. Clarke, R.C. Burton, and Y.C. Smart The antitumor effect of levamisole in mice are mediated by NC-1.1+ cells Cancer Immunol Immunother 45 1997 115 118
7. K.H. Goodrich, X. Alvarez, and R.F. Holcombe Effect of levamisole on major histocompatibility complex (MHC) class I expression in colorectal and breast carcinoma cell lines Cancer 72 1993 225 230
8. E.S. Kimball, and M.C. Fisher Levamisole effects on major histocompatibility complex and adhesion molecule expression and on myeloid cell adhesion to human colon tumor cell lines J Natl Cancer Inst 88 1996 109 116
9. R.F. Holcombe, and R.M. Stewart Augmentation of IL12-dependent Th1 cytokine production by levamisole Allergy Clin Immunol Int 9 1997 119 120
10. R.F. Holcombe, T. Milovanovic, R.M. Stewart, and T.M. Brodhag Investigating immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints Cancer Detect Prev 25 2001 183 191
11. Biological therapies for cancer: questions and answers in NCI on-line, August 16, 2004. http://cis.nci.nih.gov/fact/7_2.htm.
12. Cancer facts and figures, 2004 at American Cancer Society Inc., 2004. http://www.cancer.org/.
13. P. Jacobson-Brown, and M.G. Neuman Colon polyps and cytokines: emerging immunological mechanisms Rom J Gastroenterol 12 2003 207 214
14. T.G. Robbins, R.J. Weinstein, and R.Y. Demers Lymphocytopenia, T-lyphocyte subsets, and colorectal polyps in automotive pattern and model markers J Occup Med 33 1991 510 515
15. K.M. Murphy, and S.L. Reiner The lineage decisions of helper T-cells Nat Rev Immunol 2 12 2002 933 944
16. K. Dredge, J.B. Marriott, S.M. Todryk, and A.G. Dalgleish Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy Cancer Immunol Immunother 51 10 2002 521 531 Epub September 20, 2002
17. M.J. Smyth, K.Y. Thia, S.E. Street, E. Cretney, J.A. Trapani, and M. Taniguchi Differential tumor surveillance by natural killer (NK) and NKT-cells J Exp Med 191 2000 661 668
18. R. Martiniello, R.C. Burton, and Y.C. Smart Ly-6C+ natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of mice Int J Cancer 66 1996 532 537
19. J.J. Gozzo, and R.H. Hanson Varied in vivo properties of levamisole (LMS) on the immune response in mice Transpl Proc 11 1979 1420 1421
20. E.G. Bliznakov Immunostimulation or immunodepression? Biomedicine 26 1977 73 76
21. R.F. Holcombe, J. Jacobson, S.R. Dakhil, R.M. Stewart, K.S. Betzing, and K. Kannan Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest oncology group protocol 9009 Cancer Immunol Immunother 48 1999 533 539
22. K.I. Block, B. Boyd, N. Gonzalez, and A. Vojdani The immune system in cancer Integr Cancer Ther 1 2002 294 316